A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia

Journal of Gastroenterology

Volumn 46, Issue 8, 2011, Pages 1010-1019

  Tahara, Hiroki ^a   Takagi, Hitoshi ^a   Sato, Ken ^a   Shimada, Yasushi ^a   Tojima, Hiroki ^a   Hirokawa, Tomoyuki ^a   Ohyama, Tatsuya ^a   Horiuchi, Katsuhiko ^a   Naganuma, Atsushi ^a   Arai, Hirotaka ^a   Kakizaki, Satoru ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Interferon; Partial splenic embolization; Ribavirin; Sustained virological response; Thrombocytopenia

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG RESPONSE; FATIGUE; FEMALE; HEPATITIS C; HUMAN; HYPERSPLENISM; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; MALE; NEUTROPENIA; PARTIAL SPLENIC EMBOLIZATION; PATIENT SAFETY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; COMBINED MODALITY THERAPY; EMBOLIZATION, THERAPEUTIC; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PLATELET COUNT; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; SPLENIC ARTERY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 80052418501     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0407-9     Document Type: Article

References (37)

1. K Sato H Takagi T Ichikawa S Kakizaki M Mori 2008 Emerging therapeutic strategies for hepatitis C virus infection Curr Mol Pharmacol 1 130 150 20021428 10.2174/1874467210801020130 1:CAS:528:DC%2BD1cXmvVaku74%3D
2. Y Shiratori Y Ito O Yokosuka F Imazeki R Nakata N Tanaka, et al. 2005 Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival Ann Intern Med 142 105 114 15657158 1:CAS:528:DC%2BD2MXktVequ74%3D
3. T Poynard J McHutchison M Manns C Trepo K Lindsay Z Goodman, et al. 2002 Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 1303 1313 11984517 10.1053/gast.2002.33023 1:CAS:528:DC%2BD38Xkt1Cru74%3D (Pubitemid 34465173)
4. GT Everson JC Hoefs LB Seeff HL Bonkovsky D Naishadham ML Shiffman, et al. 2006 Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial Hepatology 44 1675 1684 17133499 10.1002/hep.21440 1:CAS:528:DC%2BD2sXislOjuw%3D%3D (Pubitemid 44953672)
5. SJ Hadziyannis H Sette Jr TR Morgan V Balan M Diago P Marcellin, et al. 2004 Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346 355 14996676 1:CAS:528:DC%2BD2cXitlOktrg%3D
6. RH Aster 1966 Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia J Clin Invest 45 645 657 5327481 10.1172/JCI105380 1:STN:280:DyaF287js1WrsA%3D%3D
7. Y Aoki K Hirai K Tanikawa 1993 Mechanism of thrombocytopenia in liver cirrhosis: kinetics of indium-111 tropolone labelled platelets Eur J Nucl Med 20 123 129 8440268 10.1007/BF00168872 1:STN:280:DyaK3s7nvVCkuw%3D%3D (Pubitemid 23075107)
8. T Nagamine T Ohtuka K Takehara T Arai H Takagi M Mori 1996 Thrombocytopenia associated with hepatitis C viral infection J Hepatol 24 135 140 8907565 10.1016/S0168-8278(96)80021-3 1:STN:280:DyaK2s%2FmtlKqug%3D%3D (Pubitemid 26059114)
9. N Afdhal J McHutchison R Brown I Jacobson M Manns F Poordad, et al. 2008 Thrombocytopenia associated with chronic liver disease J Hepatol 48 1000 1007 18433919 10.1016/j.jhep.2008.03.009 1:CAS:528:DC%2BD1cXlvVSks7o%3D
10. KW Kercher AM Carbonell BT Heniford BD Matthews DM Cunningham RW Reindollar 2004 Laparoscopic splenectomy reverses thrombocytopenia in patients with hepatitis C cirrhosis and portal hypertension J Gastrointest Surg. 8 120 126 14746844 10.1016/j.gassur.2003.10.009 (Pubitemid 38117286)
11. JH Zhu YD Wang ZY Ye T Zhao YW Zhu ZJ Xie, et al. 2009 Laparoscopic versus open splenectomy for hypersplenism secondary to liver cirrhosis Surg Laparosc Endosc Percutan Tech. 19 258 262 19542858 10.1097/SLE.0b013e3181a6ec7c
12. Y Wang X Zhan Y Zhu Z Xie J Zhu Z Ye 2010 Laparoscopic splenectomy in portal hypertension: a single-surgeon 13-year experience Surg Endosc 24 1164 1169 20033218 10.1007/s00464-009-0744-4
13. MA Amin MM el-Gendy IE Dawoud A Shoma AM Negm TA Amer 2009 Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients World J Surg 33 1702 1710 19513783 10.1007/s00268-009-0095-2
14. HY Wang SC Shih SC Lin WS Chang TE Wang FJ Lin, et al. 2008 Partial splenic embolization: 12-month hematological effects and complications Hepatogastroenterology 55 1838 1842 19102404
15. B Palsson M Hallén AM Forsberg A Alwmark 2003 Partial splenic embolization: long-term outcome Langenbecks Arch Surg. 387 421 426 12607123 (Pubitemid 36343038)
16. T Tajiri M Onda H Yoshida Y Mamada N Taniai T Kumazaki 2002 Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis Hepatogastroenterology 49 1445 1448 12239963
17. K Sakata K Hirai K Tanikawa 1996 A long-term investigation of transcatheter splenic arterial embolization for hypersplenism Hepatogastroenterology 43 309 318 8682485 1:STN:280:DyaK283mvVyjtQ%3D%3D (Pubitemid 26083805)
18. B Sangro I Bilbao I Herrero C Corella J Longo O Beloqui, et al. 1993 Partial splenic embolization for the treatment of hypersplenism in cirrhosis Hepatology. 18 309 314 8340060 10.1002/hep.1840180214 1:STN:280: DyaK3szjvFOgsg%3D%3D (Pubitemid 23225101)
19. JG McHutchison G Dusheiko ML Shiffman M Rodriguez-Torres S Sigal M Bourliere, et al. 2007 Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C N Engl J Med 357 2227 2236 18046027 10.1056/NEJMoa073255 1:CAS:528:DC%2BD2sXhsVSmt7fE (Pubitemid 350190753)
20. T Akahoshi M Tomikawa D Korenaga K Ikejiri M Saku K Takenaka 2010 Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism Surg Endosc 24 680 685 19690915 10.1007/s00464-009-0653-6
21. K Ikezawa M Naito T Yumiba K Iwahashi Y Onishi H Kita, et al. 2010 Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection J Viral Hepat. 17 488 492 19840366 1:STN:280:DC%2BC3cnotFSitQ%3D%3D
22. D Morihara M Kobayashi K Ikeda Y Kawamura H Saneto H Yatuji, et al. 2009 Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia Hepatol Res. 39 439 447 19207581 10.1111/j.1872-034X.2008.00481.x 1:CAS:528: DC%2BD1MXhsFemsbnN
23. R Bárcena A Moreno JR Foruny J Blázquez J Graus JM Riesco, et al. 2010 Partial splenic embolization and peg-IFN plus RBV in liver transplanted patients with hepatitis C recurrence: safety, efficacy and long-term outcome Clin Transplant 24 366 374 19863593 10.1111/j.1399-0012.2009. 01081.x
24. Y Miyake M Ando E Kaji T Toyokawa M Nakatsu M Hirohata 2008 Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia Hepatol Res. 38 980 986 18657124 10.1111/j.1872-034X.2008.00357.x 1:CAS:528:DC%2BD1cXht12hs7bN
25. N Sohara H Takagi S Kakizaki K Sato M Mori 2006 The use of partial splenic artery embolization made it possible to administer interferon and ribavirin therapy in a liver transplant patient with fibrosing cholestatic hepatitis C complicated with thrombocytopenia Transpl Int 19 255 257 16441778 10.1111/j.1432-2277.2006.00263.x
26. A Moreno R Bárcena J Blázquez C Quereda L Gil-Grande J Sánchez, et al. 2004 Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirin Antivir Ther. 9 1027 1030 15651761 (Pubitemid 40040276)
27. JR Foruny J Blázquez A Moreno R Bárcena L Gil-Grande C Quereda, et al. 2005 Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization Eur J Gastroenterol Hepatol 17 1157 1164 16215426 10.1097/00042737-200511000- 00002 1:CAS:528:DC%2BD2MXhtVymt7fF (Pubitemid 41527431)
28. AS Lok MG Ghany ZD Goodman EC Wright GT Everson RK Sterling, et al. 2005 Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort Hepatology. 42 282 292 15986415 10.1002/hep.20772 (Pubitemid 41061080)
29. K Zhou LG Lu 2009 Assessment of fibrosis in chronic liver diseases J Dig Dis. 10 7 14 19236541 10.1111/j.1751-2980.2008.00356.x
30. G Colloredo M Guido A Sonzogni G Leandro 2003 Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease J Hepatol 39 239 244 12873821 10.1016/S0168-8278(03) 00191-0 (Pubitemid 36920560)
31. A Mangia R Santoro N Minerva GL Ricci V Carretta M Persico, et al. 2005 Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 N Engl J Med 352 2609 2617 15972867 10.1056/NEJMoa042608 1:CAS:528: DC%2BD2MXls1ajsro%3D (Pubitemid 41007847)
32. Y Inoue N Hiramatsu T Oze T Yakushijin K Mochizuki H Hagiwara, et al. 2010 Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses J Viral Hepat. 17 336 344 19678893 10.1111/j.1365-2893.2009.01182.x 1:STN:280:DC%2BC3czhsFektQ%3D%3D
33. Numata M, Kagawa T, Kojima S, Hirose S, Nagata N, Shiraishi K, et al. Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis C. Hepat Res Treat. 2010;2010:702-48.
34. T Okanoue Y Itoh H Hashimoto K Yasui M Minami T Takehara, et al. 2009 Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study J Gastroenterol 44 952 963 19517057 10.1007/s00535-009-0087-x 1:CAS:528:DC%2BD1MXhtFCntr%2FL
35. Y Tanaka N Nishida M Sugiyama M Kurosaki K Matsuura N Sakamoto, et al. 2009 Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 1105 1109 19749757 10.1038/ng.449 1:CAS:528:DC%2BD1MXhtFaju73K
36. H Hayashi T Beppu K Okabe T Masuda H Okabe H Baba 2008 Risk factors for complications after partial splenic embolization for liver cirrhosis Br J Surg 95 744 750 18412294 10.1002/bjs.6081 1:STN:280:DC%2BD1c3pt1egsw%3D%3D
37. K Zhu X Meng J Qian M Huang Z Li S Guan, et al. 2009 Partial splenic embolization for hypersplenism in cirrhosis: a long-term outcome in 62 patients Dig Liver Dis. 41 411 416 19070555 10.1016/j.dld.2008.10.005 1:STN:280:DC%2BD1MzhsVensA%3D%3D